BINARY Non-Vascular Luminal Intervention System
BINARY completes Hanglok-Tech’s interventional robotics portfolio as a non-vascular luminal intervention system focused on lung cancer diagnosis. The platform approaches pulmonary lesions through bronchoscopy pathways, complementing the percutaneous approach offered by SGNIO.
Product Overview
Early lung cancer detection significantly improves patient outcomes, driving demand for technologies that can accurately diagnose pulmonary nodules. BINARY addresses this clinical need through bronchoscopy-based intervention, reaching lesions via the natural airway rather than through the chest wall.
The system represents the third pillar of Hanglok-Tech’s strategy to cover percutaneous, endovascular, and non-vascular luminal interventional approaches. Company communications describe BINARY as providing “insights into lung cancer” through advanced diagnostic capabilities.
Key Features
Designed for lung cancer diagnosis via natural airway access, Hanglok-Tech’s BINARY reaches pulmonary lesions through bronchoscopy pathways as the non-vascular complement to the percutaneous SGNIO platform.
- Bronchoscopy Approach: Accesses pulmonary lesions through natural airways
- Navigation Integration: Compatible with Hanglok-Tech’s broader surgical planning infrastructure
- Diagnostic Focus: Optimized for tissue sampling and lesion characterization
- Complementary Design: Works alongside SGNIO to provide full lung cancer diagnostic options
Technical Specifications
Designed for bronchoscopy-based lung cancer diagnosis, BINARY from Hanglok-Tech targets pulmonary nodule biopsy and peripheral lesion sampling through airway access integrated with the company’s data center platform.
| Parameter | Specification |
|---|---|
| Approach | Non-vascular luminal (bronchoscopy) |
| Target Application | Lung cancer diagnosis |
| Integration | Hanglok-Tech data center platform |
| Development Status | Earlier stage than SGNIO/MULLER |
Clinical Applications
BINARY targets diagnostic bronchoscopy applications:
- Pulmonary nodule biopsy through airway access
- Lung cancer staging procedures
- Peripheral lesion sampling
- Cases where percutaneous approach presents higher risk
The platform offers an alternative to percutaneous biopsy for lesions accessible through the bronchial tree.
Regulatory Status
| Region | Status | Date |
|---|---|---|
| China (NMPA) | Development Stage | - |
| Europe (CE) | Not Applied | - |
| United States (FDA) | Not Applied | - |
BINARY appears to be at an earlier development stage compared to SGNIO and MULLER, which have both entered clinical trials. Specific regulatory timeline information has not been disclosed.
Frequently Asked Questions
How does BINARY differ from SGNIO?
While both target lung cancer diagnosis, SGNIO uses a percutaneous (through the chest wall) approach under CT guidance, whereas BINARY accesses lesions through the airways via bronchoscopy. The choice between approaches depends on lesion location and patient factors.
What is the current development status of BINARY?
BINARY is in development as part of Hanglok-Tech’s product pipeline. Unlike SGNIO and MULLER, which entered clinical trials in 2022, BINARY appears to be at an earlier stage with limited public information available about its regulatory timeline.
Can BINARY and SGNIO be used together?
The systems address different clinical scenarios and approaches to lung cancer diagnosis. Healthcare providers could potentially use both platforms depending on individual patient needs and lesion characteristics.
Browse related categories
Sources
Publicly available references used for the data on this page. See data methodology for verification standards.